ohoh schreef op 20 juni 2019 10:45:
Deze is van vorige week dus mogelijk al gedeeld op het forum (in dat geval excuses).
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with a price target of $2.50. The company’s shares opened today at $0.85, close to its 52-week low of $0.74.
“Valuation and potential impediments to achieving it. We reiterate our Buy rating and €2.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include, lack of meaningful market penetration, failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”www.analystratings.com/articles/analy...